AstraZeneca PLC (NASDAQ:AZN) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company announced ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

Cambridge: AstraZeneca has announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval ...

FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that ...

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

Investing.com -- AstraZeneca (NASDAQ: AZN) on Monday night received accelerated approval from the U.S. Food and Drug ...

AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC ...

Drugmaker AstraZeneca's Datroway has been approved in the US for adult patients with previously treated advanced EGFR-mutated non-small cell lung cancer.